The minimum total value of this contract is $930,000, the majority of which will be recognized in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 130 days to over $3.7 million.
According to the company, the SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
Duncan Ross, CEO of AtCor Medical, said: “We continue to execute on our strategy in pursuing the pharmaceutical clinical trials market. This new contract is not only evidence of the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical clinical trials but also reinforces its emerging importance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our growing list of pharmaceutical trial customers.”